Boron Neutron Capture Therapy and Radiation Synovectomy Research at the Massachusetts Institute of Technology Research Reactor

Harling, O. K.; Yanch, J. C.; Choi, Jaehyuk; Solares, Guido R.; Rogus, Ronald D.; Moulin, Damien J.; Johnson, L. Scott; Ölmez, I.; Wirdzek, S.; Bernard, John A.; Zamenhof, Robert G.; Nwanguma, Charles I.; Wazer, David E.; Saris, Stephen C.; Madoc‐Jones, Hywel; Sledge, Clement B.; Shortkroff, Sonya

doi:10.13182/nse92-a23907

Cited by 19 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism underlying this is selective uptake of BPA by tumor cells as compared to normal brain. We have demonstrated this phenomenon in situ with murine gliomas [7] in which the tumor to normal brain concentration ratios were 3.54: 1. It is unclear why tumor cells preferentially accumulate BPA.…”

Section: Animal Experimentsmentioning

confidence: 67%

Preparations for phase I clinical trials of boron neutron capture therapy at the mit reactor and the New England Medical Center

Harling

Zamenhof

Solares

et al. 1994

Radation Oncology Invest

Self Cite

View full text Add to dashboard Cite

Section: Animal Experimentsmentioning

confidence: 67%

Preparations for phase I clinical trials of boron neutron capture therapy at the mit reactor and the New England Medical Center

Harling

Zamenhof

Solares

et al. 1994

Radation Oncology Invest

Self Cite

View full text Add to dashboard Cite

“…A general discussion of BNCT can be found in several references. 2,3 Nowadays, BNCT facilities have spread over the world, and clinical trials are being performed in several places. Not only were epithermal beams used for deep-seated tumors but also thermal beams were applied for the treatment of superficial tumors such as skin melanomas.…”

Section: Introductionmentioning

confidence: 99%

Boron neutron capture therapy of skin melanomas at the RA-6 reactor: A procedural approach to beam set up and performance evaluation for upcoming clinical trials

et al. 2003

View full text Add to dashboard Cite

This article reports on the progress of the modeling and experimental characterization of the RA-6 reactor neutron beam, designed for the upcoming BNCT clinical trials of skin melanoma, and presents the first theoretical analysis of such beam performance. The aspects relating to surface source modeling and assessment, beam dosimetry, treatment planning system calibration, and treatment planning optimization are presented herein. Several methods and criteria were established in order to provide guidance for future clinical studies conducted in this facility. Following a realistic model, the theoretical analysis was based on a clinical case of malignant melanoma in extremities. Owing to the complex geometry of the tumor, this particular clinical case represents one of the most difficult lesions to be treated. This article discusses the thorough evaluation stage that has led to the optimization of the treatment planning procedure. Two candidate plans were proposed, and dose-volume distributions in the target volume were evaluated on the basis of the application of a series of criteria that define the critical normal structures which limit the dose delivered. In spite of the complexity of the clinical case under review, results showed that only 4% of the tumor volume is underdosed in cases of mean blood 10B concentration values, even in the most unfavorable analysis. The overall results suggest that this BNCT facility is prepared to rigorously explore the clinical efficacy of the RA-6 beam and the BNCT treatment modality for peripheral melanomas.

show abstract

“…17 Computer analysis of tumor tissue autoradiographs can provide the cell and source spatial information with a reso-lution on the order of one micrometer on a two-dimensional ͑2D͒ section. [18][19][20] The spatial resolution along the longitudinal axis depends on the thickness of the sections, typically, 2-8 m. In theory, aligned serial section autoradiographs allow the three-dimensional ͑3D͒ reconstruction of the activity or boron within the specimen, from which estimates of the absorbed dose rate ͑radioimmunotherapy͒ or absorbed dose ͑boron capture therapy͒ can be obtained. Such data can be used to calculate the absorbed dose/absorbed dose rate distribution to a cell population within the specimen.…”

Section: Introductionmentioning

confidence: 99%

Estimate of absorbed dose based on two-dimensional autoradiographic information in internal radionuclide therapy

Humm

Chin

2001

Med. Phys.

View full text Add to dashboard Cite

In radiation therapies using radionuclides emitting short-range particles, such as radioimmunotherapy or boron neutron capture therapy, the biological effects are strongly affected by the heterogeneity of the absorbed dose distribution delivered to tumor cells. The three-dimensional (3D) information of the source distribution at the cellular level is required to accurately determine the absorbed dose distribution to the individual tumor cells. Two-dimensional distribution of cell and nuclide with a resolution of 1 microm can be obtained from individual tissue sections by microautoradiography. To obtain such information in 3D, an ideal approach would be to align the serial tissue sections from a block and analyze all of them. This is straightforward in theory, but extremely difficult in practice. Furthermore, every section in the block has to be processed and analyzed, and the usage of the data from this laborious work is very inefficient. An approach presented here is to estimate the absorbed dose based on individual sections without 3D reconstruction. It is realistically workable since it avoids the most difficult task of alignment for the serial tissue sections. In addition, the absorbed dose can be estimated based on a limited number of noncontiguous sections. The validity of this approach has been tested by a Monte Carlo simulation for two representative radionuclide configurations: (a) a uniform distribution of sources and (b) a cell membrane bound source distribution. With only a limited number of sampling sections, the uncertainties in the dose estimation were estimated to approximately 15% for short-range particles.

show abstract

Boron Neutron Capture Therapy and Radiation Synovectomy Research at the Massachusetts Institute of Technology Research Reactor

Cited by 19 publications

References 9 publications

Preparations for phase I clinical trials of boron neutron capture therapy at the mit reactor and the New England Medical Center

Preparations for phase I clinical trials of boron neutron capture therapy at the mit reactor and the New England Medical Center

Boron neutron capture therapy of skin melanomas at the RA-6 reactor: A procedural approach to beam set up and performance evaluation for upcoming clinical trials

Estimate of absorbed dose based on two-dimensional autoradiographic information in internal radionuclide therapy

Contact Info

Product

Resources

About